Pfizer Inc. $PFE Shares Purchased by SeaCrest Wealth Management LLC

Key Points

• SeaCrest Wealth Management LLC increased its holdings in Pfizer Inc. by 26.7% during the second quarter, owning a total of 86,556 shares now valued at approximately $2.1 million as per recent SEC filings.
• Analysts have set new price targets for Pfizer, with Citigroup raising the target to $26.00 and Bank of America to $28.00, while the consensus price target stands at $28.12.
• Pfizer reported a 10.3% year-over-year revenue increase in its last earnings report, with earnings per share of $0.78, surpassing estimates of $0.58.

SeaCrest Wealth Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 26.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86,556 shares of the biopharmaceutical company's stock after buying an additional 18,226 shares during the quarter. SeaCrest Wealth Management LLC's holdings in Pfizer were worth $2,098,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PFE. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the first quarter valued at approximately $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter valued at approximately $28,000. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

NYSE:PFE traded down $0.12 during midday trading on Friday, reaching $24.03. The stock had a trading volume of 86,201,583 shares, compared to its average volume of 39,901,288. The firm has a fifty day simple moving average of $24.63 and a two-hundred day simple moving average of $24.21. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market cap of $136.62 billion, a P/E ratio of 12.78, a P/E/G ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.60 EPS. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.